دورية أكاديمية
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
| العنوان: | Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party. |
|---|---|
| المؤلفون: | Duque-Afonso J; Department of Hematology/Oncology, Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany. jesus.duque.afonso@uniklinik-freiburg.de., Finke J; Department of Hematology/Oncology, Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany., Ngoya M; EBMT Statistical Unit, INSERM UMRs 938, Hôpital Saint Antoine, Paris, France., Galimard JE; EBMT Statistical Unit, INSERM UMRs 938, Hôpital Saint Antoine, Paris, France., Craddock C; Birmingham Centre for Cellular Therapy and Transplantation, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, UK., Raj K; Department of Haematology, University College London Hospital, London, UK., Bloor A; The Christie NHS Foundation Trust, Stem Cell Transplantation Unit, University of Manchester, Manchester, UK., Nicholson E; Department of Haematology, Royal Marsden Hospital, London, UK., Eder M; Department of Haematology, Hannover Medical School, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany., Kim O; Department of Haematology, Southampton General Hospital, Haematology, Oncology & Paediatrics, Southampton, UK., Valerius T; Department of Medicine II, University Medical Center Schleswig-Holstein, Campus Kiel, Section of Stem Cell Transplantation and Immunotherapy, Kiel, Germany., Snowden JA; Department of Hematology, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, UK., Tholouli E; Clinical Haematology Department, Manchester Royal Infirmary, Manchester, UK., Crawley C; Department of Haematology, Addenbrookes Hospital, Cambridge, UK., Collin M; Adult HSCT unit, Northern Centre for Bone Marrow Transplantation, Freeman Hospital, Newcastle Tyne, UK., Wilson KMO; Department of Haematology, University Hospital of Wales, Cardiff, UK., Gadisseur A; Department of Hematology, Antwerp University Hospital (UZA), Antwerp Edegem, Belgium., Protheroe R; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK., Wagner-Drouet EM; Department of Hematology, University Medical Center Mainz, Oncology and Pneumology, Mainz, Germany., Savani BN; Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA., Spyridonidis A; University Hospital of Patras, Patras, Greece., Ciceri F; University Vita-Salute, IRCCS San Raffaele Scientific Institute, Milan, Italy., Nagler A; Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel., Mohty M; Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France. mohamad.mohty@inserm.fr. |
| المصدر: | Bone marrow transplantation [Bone Marrow Transplant] 2024 Feb; Vol. 59 (2), pp. 247-254. Date of Electronic Publication: 2023 Dec 02. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2003->: London : Nature Publishing Group Original Publication: Basingstoke, Hampshire : Scientific & Medical Division, Macmillan Press, c1986- |
| مواضيع طبية MeSH: | Leukemia, Myeloid, Acute* , Hematopoietic Stem Cell Transplantation*/methods , Graft vs Host Disease*/etiology, Vidarabine/*analogs & derivatives, Humans ; Adult ; Melphalan/pharmacology ; Melphalan/therapeutic use ; Carmustine ; Thiotepa/pharmacology ; Thiotepa/therapeutic use ; Busulfan ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Transplantation Conditioning/methods ; Transplantation, Homologous/adverse effects ; Recurrence ; Pathologic Complete Response ; Alkylating Agents ; Retrospective Studies |
| مستخلص: | Conditioning protocols for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) are being developed continuously to improve their anti-leukemic efficacy and reduce their toxicity. In this study, we compared the conditioning protocol of fludarabine with melphalan 140 mg/m 2 (FluMel) with conditioning protocols based on this same backbone but with an additional alkylating agent i.e., either fludarabine/BCNU (also known as carmustine)/melphalan (FBM), or fludarabine/thiotepa/melphalan (FTM) 110 mg/m 2 . We included 1272 adult patients (FluMel, n = 1002; FBM/FTM, n = 270) with acute myeloid leukemia (AML) with intermediate/poor cytogenetic risk in first complete remission (CR) from the registry of the EBMT Acute Leukemia Working Party. Despite patients in the FBM/FTM group were older (64.1 years vs. 59.8 years, p < 0.001) and had a worse Karnofsky performance score (KPS < 90, 33% vs. 24%, p = 0.003), they showed a better overall survival (OS) (2 y OS: 68.3% vs. 58.1%, p = 0.02) and less non-relapse mortality (NRM) (2 y NRM: 15.8% vs. 22.2%, p = 0.009) compared to patients treated with FluMel. No significant differences were observed in relapse incidence (RI) (2 y RI: 24.9% vs. 23.7%, p = 0.62). In conclusion, the addition of a second alkylating agent (BCNU/carmustine or thiotepa) to FluMel as FBM/FTM conditioning, improves OS in AML patients in first CR with intermediate/poor risk cytogenetics after allo-HCT. (© 2023. The Author(s).) |
| References: | Bone Marrow Transplant. 2022 Aug;57(8):1269-1276. (PMID: 35568756) Blood. 2012 Jul 12;120(2):473-6. (PMID: 22645178) J Clin Oncol. 2021 Mar 1;39(7):768-778. (PMID: 33373276) Biol Blood Marrow Transplant. 2020 Apr;26(4):698-703. (PMID: 31875522) Clin Hematol Int. 2021 Aug 19;3(4):153-160. (PMID: 34938987) Oncotarget. 2017 Dec 15;9(3):3379-3393. (PMID: 29423053) Bone Marrow Transplant. 2012 Oct;47(10):1287-93. (PMID: 22327127) Br J Haematol. 2008 Nov;143(4):548-51. (PMID: 18986389) Blood Adv. 2018 Aug 28;2(16):2095-2103. (PMID: 30135184) Blood. 2020 Feb 6;135(6):449-452. (PMID: 31826244) Bone Marrow Transplant. 2020 Jun;55(6):1114-1125. (PMID: 31996792) Transplant Cell Ther. 2021 Nov;27(11):921.e1-921.e10. (PMID: 34403791) Haematologica. 2020 Oct 09;105(12):2716-2729. (PMID: 33054108) Biol Blood Marrow Transplant. 2009 Dec;15(12):1563-70. (PMID: 19896080) Bone Marrow Transplant. 2010 Mar;45(3):429-36. (PMID: 19668237) Biol Blood Marrow Transplant. 2013 Jan;19(1):117-22. (PMID: 22940057) Biol Blood Marrow Transplant. 2018 Nov;24(11):2277-2284. (PMID: 29964193) J Clin Oncol. 2003 Apr 15;21(8):1480-4. (PMID: 12697870) Clin Hematol Int. 2019 Dec 17;2(1):2-4. (PMID: 34595436) Lancet Oncol. 2015 Nov;16(15):1525-1536. (PMID: 26429297) Blood. 2004 Aug 1;104(3):857-64. (PMID: 15073038) Leuk Lymphoma. 2012 May;53(5):901-6. (PMID: 21988645) Blood. 2016 Jan 28;127(4):503-12. (PMID: 26644451) Am J Hematol. 2022 Aug;97(8):1023-1034. (PMID: 35617104) Blood. 2005 May 15;105(10):4147-8. (PMID: 15867422) Bone Marrow Transplant. 2021 Jan;56(1):110-120. (PMID: 32591641) Blood. 2008 Jul 15;112(2):415-25. (PMID: 18451310) Leuk Lymphoma. 2007 Apr;48(4):759-66. (PMID: 17454635) Biol Blood Marrow Transplant. 2002;8(9):468-76. (PMID: 12374451) Bone Marrow Transplant. 2021 Jul;56(7):1651-1664. (PMID: 33623153) Bone Marrow Transplant. 2000 Aug;26(3):243-50. (PMID: 10967561) Blood. 2013 Jan 31;121(5):849-57. (PMID: 23165479) Leukemia. 2007 Oct;21(10):2109-16. (PMID: 17690701) Bone Marrow Transplant. 2022 Nov;57(11):1664-1670. (PMID: 35982219) Cancer. 2015 Apr 1;121(7):1048-55. (PMID: 25424330) |
| المشرفين على المادة: | Q41OR9510P (Melphalan) U68WG3173Y (Carmustine) 905Z5W3GKH (Thiotepa) G1LN9045DK (Busulfan) P2K93U8740 (fludarabine) 0 (Alkylating Agents) FA2DM6879K (Vidarabine) |
| تواريخ الأحداث: | Date Created: 20231201 Date Completed: 20240209 Latest Revision: 20240304 |
| رمز التحديث: | 20240305 |
| مُعرف محوري في PubMed: | PMC10849951 |
| DOI: | 10.1038/s41409-023-02150-w |
| PMID: | 38040842 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!